查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108293

再生醫學市場分析及預測（至2035年）：依類型、產品、服務、技術、應用、材料類型、設備、製程及最終用戶分類

Regenerative Medicine Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Material Type, Device, Process, End User
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球再生醫學市場預計將從2025年的413億美元成長到2035年的1,946億美元，複合年成長率（CAGR）為16.8%。再生醫學市場呈現中等程度的整合結構，其中細胞療法佔最大佔有率，這主要得益於其在癌症、肌肉骨骼疾病和遺傳性疾病等領域的廣泛應用；其次是基因療法和組織工程。推動該市場成長的因素包括幹細胞技術和CRISPR基因編輯技術的進步、臨床試驗的增加以及再生醫學法規核准的不斷擴大。競爭格局主要由專注於創新、合作和擴大生產能力的領先生物技術和製藥公司所構成。例如，2025年1月，Geneta Science與AGC Biologics深化合作，共同建立一座專門用於生產其細胞療法產品的GMP生產設施，從而提升其先進細胞療法的產能。

按類型分類，細胞療法將在2025年引領再生醫學市場成長，這主要得益於其廣泛的臨床應用、在先進治療研發中日益成長的應用以及在多個疾病領域的強大影響力。細胞療法利用活細胞修復受損組織、替換功能異常細胞並恢復生物功能，在腫瘤學、整形外科、心血管疾病和神經系統疾病等領域具有巨大的價值。幹細胞技術、免疫療法和細胞製造過程的快速發展正在推動其應用。生技和製藥公司加大投資、拓展臨床研發管線以及法規核准的不斷增加，持續鞏固細胞療法在全球再生醫學市場的主導地位。

市場區隔
類型 細胞療法、基因療法、組織工程、幹細胞技術、免疫療法及其他
產品 支架、生物材料、幹細胞產品、基因編輯工具、細胞培養產品等。
服務 再生醫學諮詢、再生醫學製造、再生醫學研究與發展及其他服務。
科技 CRISPR、TALEN、鋅指核酸酶、細胞培養技術、反應器技術、3D生物列印等。
目的 整形外科/肌肉骨骼疾病、皮膚科、循環系統、神經科、腫瘤科、糖尿病科、眼科、創傷護理、其他
材料類型 天然生物材料、合成生物材料、水凝膠、奈米材料等。
裝置 反應器、細胞增殖系統、細胞分選系統及其他
過程 體內、體內、其他
最終用戶 醫院、診所、研究機構、生技公司、製藥公司、學術機構及其他

按技術分類，3D生物列印領域預計將在預測期內實現最快成長，這主要得益於其建構複雜生物結構、個人化組織和高精度支架的能力。該技術使研究人員能夠複製天然組織結構，從而推動組織工程、器官再生和個人化醫療領域的創新。再生醫學研究投入的增加、生物材料的進步以及生物技術公司、學術機構和醫療機構之間合作的不斷深化，都在加速3D生物列印解決方案的普及應用。此外，為解決器官短缺問題、改善移植效果和開發個人化療法不斷成長的創新需求，預計將進一步推動該領域的快速發展。

區域概覽

2025年，北美在再生醫學市場主導，這得益於其先進的醫療基礎設施、強大的生物技術生態系統、廣泛的研究活動以及對細胞和基因療法開發的大量投資。美國是最大的貢獻者，這得益於眾多大型企業和製藥公司、大量的臨床試驗機構以及有利於再生醫學核准的法規環境。加拿大也透過政府主導的研究舉措和對先進醫療技術的加大投資，為該地區的成長做出了貢獻。學術機構、研究組織和產業相關人員之間的密切合作，進一步鞏固了北美在全球再生醫學市場的主導地位。

預計在預測期內，亞太地區再生醫學市場將實現最快成長，這主要得益於醫療保健領域投資的增加、生物技術能力的提升、研究活動的活性化以及大量患者未被滿足的醫療需求。中國、日本、韓國和印度等國家在幹細胞研究、基因治療和組織工程應用領域均取得了快速進展。政府支持生物技術創新的舉措、擴大臨床試驗活動以及加強區域和全球醫療保健公司之間的合作，都在加速市場擴張。此外，醫療基礎設施的改善和先進療法的日益普及，預計也將進一步推動全部區域再生醫學的快速發展。

主要趨勢和促進因素

幹細胞技術的進步

由於幹細胞技術的不斷進步，再生醫學市場正經歷顯著成長。幹細胞分離、增殖和分化技術的創新，推動了針對神經系統疾病、心血管疾病和肌肉骨骼損傷等疾病的先進療法的開發。這些技術透過實現針對每位患者最佳化的細胞療法，促進了個人化再生醫學的發展。生技公司、製藥公司和研究機構不斷增加的投資，加速了幹細胞應用領域的創新。此外，細胞生產流程和品管的改進，也提高了基於幹細胞的再生醫學的規模化應用和商業化潛力。

細胞和基因治療的擴展

再生醫學市場的發展主要得益於細胞和基因療法在治療複雜且以往難以治癒的疾病方面應用日益廣泛。基因編輯技術（包括CRISPR技術）的進步以及基因修飾細胞療法的開發，正在拓展腫瘤、遺傳性疾病和罕見疾病等領域的治療選擇。臨床試驗活動的活性化、法規核准的進展以及製藥和生物技術公司的投資，正在加速這些療法的商業化。隨著再生醫學方法著眼於疾病的根本機製而非僅僅緩解症狀，全球對創新治療方案的需求也不斷成長。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 細胞療法
    • 基因治療
    • 組織工程
    • 幹細胞技術
    • 免疫療法
    • 其他
  • 市場規模及預測：依產品分類
    • 鷹架
    • 生物材料
    • 幹細胞產品
    • 基因編輯工具
    • 細胞培養產品
    • 其他
  • 市場規模及預測：依技術分類
    • CRISPR
    • TALEN
    • 鋅指核酸酶
    • 細胞培養技術
    • 反應器技術
    • 3D生物列印
    • 其他
  • 市場規模及預測：依應用領域分類
    • 整形外科/肌肉骨骼疾病
    • 皮膚科
    • 循環系統
    • 神經科
    • 腫瘤學
    • 糖尿病
    • 眼科
    • 創傷護理
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究機構
    • 生技公司
    • 製藥公司
    • 學術機構
    • 其他
  • 市場規模及預測：依製程分類
    • 體內
    • 體外
    • 其他
  • 市場規模及預測：依服務分類
    • 再生醫學諮詢
    • 再生醫學製造
    • 再生醫學研究與開發
    • 其他
  • 市場規模及預測：依設備分類
    • 反應器
    • 細胞增殖系統
    • 細胞分選系統
    • 其他
  • 市場規模及預測：依材料類型分類
    • 天然生物材料
    • 合成生物材料
    • 水凝膠
    • 奈米材料
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Novartis
  • Medtronic
  • Stryker
  • Amgen
  • Gilead Sciences
  • Baxter International
  • Vertex Pharmaceuticals
  • Biogen
  • Regeneron Pharmaceuticals
  • Astellas Pharma
  • Organogenesis
  • Vericel Corporation
  • Osiris Therapeutics
  • Mesoblast
  • Fate Therapeutics
  • Bluebird Bio
  • Sangamo Therapeutics
  • Athersys
  • Pluristem Therapeutics
  • Cytori Therapeutics

第9章 關於我們

簡介目錄
Product Code: GIS21372

The global regenerative medicine market is projected to grow from $41.3 billion in 2025 to $194.6 billion by 2035, at a compound annual growth rate (CAGR) of 16.8%. The Regenerative Medicine Market is characterized by a moderately consolidated structure, with cell therapy representing the leading segment due to its expanding applications in oncology, musculoskeletal disorders, and genetic diseases, followed by gene therapy and tissue engineering. The market is driven by advancements in stem cell technologies, CRISPR-based gene editing, increasing clinical trials, and rising regulatory approvals for regenerative therapies. The competitive landscape includes major biotechnology and pharmaceutical companies focusing on innovation, partnerships, and manufacturing expansion. For instance, in January 2025, Genenta Science strengthened its agreement with AGC Biologics to establish a dedicated GMP manufacturing suite for its cell therapy product, enhancing production capabilities for advanced cell-based therapies.

Based on Type, the Cell Therapy segment dominated the Regenerative Medicine Market in 2025 due to its extensive clinical applications, increasing adoption in advanced therapeutic development, and strong presence across multiple disease areas. Cell therapy involves the use of living cells to repair damaged tissues, replace dysfunctional cells, and restore biological functions, making it highly valuable in oncology, orthopedic disorders, cardiovascular diseases, and neurological conditions. Growing advancements in stem cell technologies, immune cell therapies, and cell manufacturing processes are accelerating its adoption. Increasing investments from biotechnology and pharmaceutical companies, expanding clinical pipelines, and rising regulatory approvals continue to strengthen the leadership position of cell therapy in the global regenerative medicine market.

Market Segmentation
TypeCell Therapy, Gene Therapy, Tissue Engineering, Stem Cell Therapy, Immunotherapy, Others
ProductScaffolds, Biomaterials, Stem Cell Products, Gene Editing Tools, Cell Culture Products, Others
ServicesRegenerative Medicine Consulting, Regenerative Medicine Manufacturing, Regenerative Medicine R&D, Others
TechnologyCRISPR, TALEN, Zinc Finger Nucleases, Cell Culture Technology, Bioreactor Technology, 3D Bioprinting, Others
ApplicationOrthopedic & Musculoskeletal Disorders, Dermatology, Cardiovascular, Neurology, Oncology, Diabetes, Ophthalmology, Wound Care, Others
Material TypeNatural Biomaterials, Synthetic Biomaterials, Hydrogels, Nanomaterials, Others
DeviceBioreactors, Cell Expansion Systems, Cell Sorting Systems, Others
ProcessIn Vivo, Ex Vivo, Others
End UserHospitals, Clinics, Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Others

Based on Technology, the 3D Bioprinting segment is projected to register the fastest growth during the forecast period, driven by its ability to develop complex biological structures, customized tissues, and advanced scaffolds with high precision. The technology enables researchers to replicate natural tissue architectures, supporting innovations in tissue engineering, organ regeneration, and personalized medicine. Increasing investments in regenerative research, advancements in biomaterials, and growing collaborations between biotechnology companies, academic institutions, and healthcare organizations are accelerating the adoption of 3D bioprinting solutions. Rising demand for innovative approaches to address organ shortages, improve transplantation outcomes, and develop patient-specific therapies is expected to further drive the rapid expansion of this segment.

Geographical Overview

North America dominated the Regenerative Medicine Market in 2025, supported by advanced healthcare infrastructure, strong biotechnology ecosystems, extensive research activities, and significant investments in cell and gene therapy development. The United States represents the largest contributor due to the presence of leading biotechnology and pharmaceutical companies, a high number of clinical trials, and a favorable regulatory environment supporting regenerative therapy approvals. Canada also contributes to regional growth through government-backed research initiatives and increasing investments in advanced medical technologies. Strong collaborations between academic institutions, research organizations, and industry players continue to strengthen North America's leadership position in the global regenerative medicine market.

Asia-Pacific region is projected to register the fastest growth in the Regenerative Medicine Market during the forecast period, driven by increasing healthcare investments, expanding biotechnology capabilities, rising research activities, and a large patient population with unmet medical needs. Countries such as China, Japan, South Korea, and India are witnessing rapid advancements in stem cell research, gene therapy, and tissue engineering applications. Government initiatives supporting biotechnology innovation, growing clinical trial activities, and increasing collaborations between regional and global healthcare companies are accelerating market expansion. Additionally, improving healthcare infrastructure and rising adoption of advanced therapeutic solutions are expected to further support the rapid growth of regenerative medicine across the region.

Key Trends and Drivers

Advances in Stem Cell Technologies:

The regenerative medicine market is witnessing significant growth due to continuous advancements in stem cell technologies. Innovations in stem cell isolation, expansion, and differentiation are enabling the development of advanced therapies for conditions such as neurological disorders, cardiovascular diseases, and musculoskeletal injuries. These technologies are supporting the development of personalized regenerative treatments by allowing patient-specific cell-based approaches. Increasing investments from biotechnology companies, pharmaceutical firms, and research institutions are accelerating innovation in stem cell applications. Additionally, improvements in cell manufacturing processes and quality control are enhancing the scalability and commercialization potential of stem cell-based regenerative therapies.

Increasing Adoption of Cell and Gene Therapies:

The regenerative medicine market is being driven by the growing adoption of cell and gene therapies for treating complex and previously difficult-to-treat medical conditions. Advances in gene editing technologies, including CRISPR-based approaches, and the development of engineered cell therapies are expanding treatment possibilities across oncology, genetic disorders, and rare diseases. Increasing clinical trial activities, regulatory approvals, and investments from pharmaceutical and biotechnology companies are accelerating the commercialization of these therapies. The ability of regenerative approaches to address underlying disease mechanisms rather than only managing symptoms is further increasing demand for innovative therapeutic solutions globally.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Services
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Material Type

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Cell Therapy
    • 4.1.2 Gene Therapy
    • 4.1.3 Tissue Engineering
    • 4.1.4 Stem Cell Therapy
    • 4.1.5 Immunotherapy
    • 4.1.6 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Scaffolds
    • 4.2.2 Biomaterials
    • 4.2.3 Stem Cell Products
    • 4.2.4 Gene Editing Tools
    • 4.2.5 Cell Culture Products
    • 4.2.6 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 CRISPR
    • 4.3.2 TALEN
    • 4.3.3 Zinc Finger Nucleases
    • 4.3.4 Cell Culture Technology
    • 4.3.5 Bioreactor Technology
    • 4.3.6 3D Bioprinting
    • 4.3.7 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Orthopedic & Musculoskeletal Disorders
    • 4.4.2 Dermatology
    • 4.4.3 Cardiovascular
    • 4.4.4 Neurology
    • 4.4.5 Oncology
    • 4.4.6 Diabetes
    • 4.4.7 Ophthalmology
    • 4.4.8 Wound Care
    • 4.4.9 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biotechnology Companies
    • 4.5.5 Pharmaceutical Companies
    • 4.5.6 Academic Institutes
    • 4.5.7 Others
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 In Vivo
    • 4.6.2 Ex Vivo
    • 4.6.3 Others
  • 4.7 Market Size & Forecast by Services (2020-2035)
    • 4.7.1 Regenerative Medicine Consulting
    • 4.7.2 Regenerative Medicine Manufacturing
    • 4.7.3 Regenerative Medicine R&D
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Bioreactors
    • 4.8.2 Cell Expansion Systems
    • 4.8.3 Cell Sorting Systems
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Material Type (2020-2035)
    • 4.9.1 Natural Biomaterials
    • 4.9.2 Synthetic Biomaterials
    • 4.9.3 Hydrogels
    • 4.9.4 Nanomaterials
    • 4.9.5 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Services
      • 5.2.1.8 Device
      • 5.2.1.9 Material Type
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Services
      • 5.2.2.8 Device
      • 5.2.2.9 Material Type
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Services
      • 5.2.3.8 Device
      • 5.2.3.9 Material Type
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Services
      • 5.3.1.8 Device
      • 5.3.1.9 Material Type
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Services
      • 5.3.2.8 Device
      • 5.3.2.9 Material Type
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Services
      • 5.3.3.8 Device
      • 5.3.3.9 Material Type
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Services
      • 5.4.1.8 Device
      • 5.4.1.9 Material Type
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Services
      • 5.4.2.8 Device
      • 5.4.2.9 Material Type
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Services
      • 5.4.3.8 Device
      • 5.4.3.9 Material Type
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Services
      • 5.4.4.8 Device
      • 5.4.4.9 Material Type
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Services
      • 5.4.5.8 Device
      • 5.4.5.9 Material Type
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Services
      • 5.4.6.8 Device
      • 5.4.6.9 Material Type
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Services
      • 5.4.7.8 Device
      • 5.4.7.9 Material Type
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Services
      • 5.5.1.8 Device
      • 5.5.1.9 Material Type
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Services
      • 5.5.2.8 Device
      • 5.5.2.9 Material Type
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Services
      • 5.5.3.8 Device
      • 5.5.3.9 Material Type
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Services
      • 5.5.4.8 Device
      • 5.5.4.9 Material Type
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Services
      • 5.5.5.8 Device
      • 5.5.5.9 Material Type
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Services
      • 5.5.6.8 Device
      • 5.5.6.9 Material Type
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Services
      • 5.6.1.8 Device
      • 5.6.1.9 Material Type
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Services
      • 5.6.2.8 Device
      • 5.6.2.9 Material Type
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Services
      • 5.6.3.8 Device
      • 5.6.3.9 Material Type
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Services
      • 5.6.4.8 Device
      • 5.6.4.9 Material Type
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Services
      • 5.6.5.8 Device
      • 5.6.5.9 Material Type

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Novartis
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Medtronic
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Stryker
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Amgen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Gilead Sciences
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Baxter International
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Vertex Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Biogen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Regeneron Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Astellas Pharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Organogenesis
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Vericel Corporation
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Osiris Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Mesoblast
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Fate Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Bluebird Bio
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Sangamo Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Athersys
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Pluristem Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cytori Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us